No Data
No Data
Zhejiang Wecome Pharmaceutical Co., Ltd. (300878.SZ) plans to sell 100% equity of Vicom Retail and Vicom Pharmacy, focusing on pharmaceutical manufacturing.
Zhejiang Wecome Pharmaceutical (300878.SZ) announced that the company intends to transfer 100% equity of its wholly-owned subsidiary, Vicom Retail, to Fuku...
Zhejiang Wecome Pharmaceutical (300878.SZ) received the summary report of the phase IIb clinical trial of silver and yellow pill.
On June 17th, Gelunhui reported that Zhejiang Wecome Pharmaceutical (300878.SZ) recently received a summary report of the multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial on the efficacy and safety of Yinhuang Drop Pill in treating recurrent aphthous ulcers (upper scorching heat pattern) . Preliminary results showed that Yinhuang Drop Pill had significant therapeutic effects in treating recurrent aphthous ulcers (upper scorching heat pattern) and was clinically safe to use.
Weikang Pharmaceutical (300878.SZ) and related personnel received a warning letter from Zhejiang Securities Regulatory Bureau
Weikang Pharmaceutical (300878.SZ) announced that the company and relevant responsible personnel received it on May 27, 2024...
Focusing on the pharmaceutical manufacturing industry, Weikang Pharmaceutical (300878.SZ) plans to sell 2 retail chain business subsidiaries
Weikang Pharmaceutical (300878.SZ) announced that Zhejiang Weikang Pharmaceutical Commercial Co., Ltd., a wholly-owned subsidiary of the company (“Weikang...
Weikang Pharmaceutical (300878.SZ) plans to pay 2.5 yuan for 10 shares to be deducted from interest on May 29
Weikang Pharmaceutical (300878.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Weikang Pharmaceutical (300878.SZ): Elected Liu Yang as Chairman of the 4th Board of Directors of the Company
Gelonghui, May 21, 丨 Weikang Pharmaceutical (300878.SZ) announced that on May 20, 2024, the first meeting of the fourth board of directors deliberated and agreed to elect Liu Yang as the chairman of the fourth board of directors for a term of three years, from the date of review and approval of the current board of directors until the end of the term of the fourth board of directors.
No Data